Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in,...
Saved in:
Main Authors: | Samit Chatterjee PhD, Wojciech G. Lesniak PhD, Sridhar Nimmagadda PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-07-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.1177/1536012117718459 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01) -
Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications
by: Hamideh Zarrinmayeh PhD, et al.
Published: (2020-06-01) -
Comment on “Surgical Margin of Resected Colorectal Liver Metastases: How Accurate Is Surgeon Prediction?”
by: Yoichiro Uchida, MD, PhD, et al.
Published: (2024-09-01) -
Health Economic Evaluation of Patients With Colorectal Liver Metastases Randomized to ALPPS or TSH: Analysis From the LIGRO Trial
by: Kristina Hasselgren, MD, PhD, et al.
Published: (2024-03-01) -
Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01)